ibandronate
information and resources from the National Cancer Institute
ibandronate
A synthetic nitrogen-containing bisphosphonate. Ibandronate inhibits farnesyl pyrophosphate synthase, resulting in a reduction in geranylgeranyl GTPase signaling proteins and apoptosis of osteoclasts. This agent increases bone mineral density, decreases bone remodeling, inhibits osteoclast-mediated bone resorption, and reduces metastases-related and corticosteroid-related bone pain. ibandronate
A synthetic nitrogen-containing bisphosphonate. Ibandronate inhibits farnesyl pyrophosphate synthase, resulting in a reduction in geranylgeranyl GTPase signaling proteins and apoptosis of osteoclasts. This agent increases bone mineral density, decreases bone remodeling, inhibits osteoclast-mediated bone resorption, and reduces metastases-related and corticosteroid-related bone pain.
|
|
|
|
news articles
Oral Ibandronate and IV May Be Equally Efficacious in Treating ... Mar 27, 2006
DG News NICE, FRANCE -- March 27, 2006 -- Patients with metastatic bone disease due to breast cancer may respond equally well to oral ibandronate (Boniva) as they do ...
Roche Says EU Approves Bonviva (Ibandronate) as Quarterly ... Mar 31, 2006
DG News Friday said they have received the European marketing authorization for the quarterly intravenous injection of the osteoporosis medication Bonviva (ibandronate ...
Innovative osteoporosis treatment, FOSAVANCE(TM), integrates two ... Mar 29, 2006
CNW Telbec (Communiqués de presse), ...and second generation bisphosphonates and other commonly used anti-osteoporosis treatments through January 2005 (etidronate, ibandronate, miacalcin, pamidronate ...
New Data Support Bondronat's Superior Renal Safety Profile Against ... Mar 24, 2006
DG News Comparison of renal impairment in multiple myeloma patients treated with zoledronic acid or ibandronate: a retrospective review. ...
Forecasts Tell Us That Bisphosphonates Will Remain the Mainstay of ... Mar 27, 2006
Genetic Engineering News, ...with 6.9% annual sales growth through our study period, driven by the emergence of two new agents: Roche/GlaxoSmithKline's ibandronate (Boniva/Bonviva) and ...
Lead May Be the Bullet Causing Osteoporosis in Senior Citizens Mar 27, 2006
SeniorJournal.com, The FDA has approved Boniva (ibandronate sodium) Injection as the first intravenous medication for the treatment of postmenopausal osteoporosis, Roche and ...
New Study Shows Women With Osteoporosis Preferred Once-Monthly ... Mar 17, 2006
DG News ...two-thirds (70%) of women with postmenopausal osteoporosis, who expressed a preference, preferred once-monthly dosing with Boniva(R) (ibandronate sodium) over ...
Double boost for Bonviva in osteoporosis Mar 20, 2006
Pharma Times (subscription), Roche and GSK will see BALTO II results as a plus for Bonviva (ibandronate) - currently the only once-monthly oral treatment for osteoporosis - especially as ...
Menopause and Bone Loss Mar 7, 2006
Journal of Clinical Endocrinology and Metabolism, These medications can be used in addition to calcium, vitamin D supplements and exercise: Bisphosphonates (alendronate, risedronate and ibandronate). ...
New Pharmaceutical Treatment Options in the Elderly Dec 14, 2005
Medscape (subscription) Ibandronate sodium (Boniva). Ibandronate sodium is a new bisphosphonate derivative that inhibits osteoclast activity and reduces bone resorption. ...
Bonviva intravenous injection for postmenopausal osteoporosis ... Nov 19, 2005
Medical News Today (press release), An intravenous (IV) injection of the new osteoporosis drug called Bonviva (ibandronate), administered every two or three months, has been shown to be highly ...
Many Patients with Osteoporosis Do Not Continue Their ... Nov 21, 2005
DG News ...be improved.". The study was funded by GlaxoSmithKline, which manufactures ibandronate (Boniva) in partnership with Roche. The medication ...
Long-Term Use of Bisphosphonates and Osteonecrosis of the Jaw ... Nov 30, 2005
Cancer Consultants (press release), ...with Zometa, 58 were treated with Aredia, 69 received both drugs sequentially, and 20 patients had treatment that included another bisphosphonate (ibandronate ...
|
|
